Inhibition of gastric secretion, specifically hydrochloric acid, is one of the most widespread treatments. More than a tenth of the adult population is treated long-term.
In addition to proton pump (H/K ATPase) inhibitors, there is a distinct renaissance of the older group - histamine H2 receptor blockers - and a newly developed group of potassium-competitive acid blockers. The overview article compares individual groups from the point of view of the mechanism of action, pharmacokinetics, pharmacodynamics, ef- ficacy and safety.